Targeting pyroptosis to treat ischemic stroke: From molecular pathways to treatment strategy

Int Immunopharmacol. 2024 Apr 29;133:112168. doi: 10.1016/j.intimp.2024.112168. Online ahead of print.ABSTRACTIschemic stroke is the primary reason for human disability and death, but the available treatment options are limited. Hence, it is imperative to explore novel and efficient therapies. In recent years, pyroptosis (a pro-inflammatory cell death characterized by inflammation) has emerged as an important pathological mechanism in ischemic stroke that can cause cell death through plasma membrane rupture and release of inflammatory cytokines. Pyroptosis is closely associated with inflammation, which exacerbates the inflammatory response in ischemic stroke. The level of inflammasomes, GSDMD, Caspases, and inflammatory factors is increased after ischemic stroke, exacerbating brain injury by mediating pyroptosis. Hence, inhibition of pyroptosis can be a therapeutic strategy for ischemic stroke. In this review, we have summarized the relationship between pyroptosis and ischemic stroke, as well as a series of treatments to attenuate pyroptosis, intending to provide insights for new therapeutic targets on ischemic stroke.PMID:38688133 | DOI:10.1016/j.intimp.2024.112168
Source: International Immunopharmacology - Category: Allergy & Immunology Authors: Source Type: research